Company

Travere

Travere Therapeutics

TVTX pharma USA

Quick answer

Travere is a pharma company (TVTX) headquartered in SAN DIEGO, CA, USA with 9 tracked pipeline programs.

Pipeline (9)

Fosmetpantotenate

Pantothenate Kinase-Associated Neurodegeneration

Phase 3 · small_molecule · terminated

1 trials project

Pegtibatinase

Homocystinuria

Phase 3 · small_molecule · active

3 trials project

sparsentan

Focal Segmental Glomerulosclerosis

Phase 3 · small_molecule · active

2 trials project

sparsentan

Immunoglobulin A Nephropathy

Phase 3 · small_molecule · active

3 trials project

RE-021 (Sparsentan)

Focal Segmental Glomerulosclerosis

Phase 2 · small_molecule · completed

1 trials project

Sparsentan

ANCA Associated Vasculitis

Phase 2 · small_molecule · active

1 trials project

RE-021, sparsentan

Healthy Subjects

Phase 1 · small_molecule · completed

1 trials project

sparsentan

Proteinuric Renal Disease

Phase 1 · small_molecule · active

1 trials project

Sparsentan

Proteinuria

Approved · small_molecule · active

Drugs (1)

sparsentan

FILSPARI

Patents (1)

US 11207299

Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases

Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

Data sources & disclaimer

This profile compiles public regulatory and patent records for informational use by pharmaceutical professionals. It is not medical advice, not investment advice, and not an official FDA, EMA, USPTO, SEC, or NIH record. NovaPharmaNews does not represent any manufacturer, sponsor, or regulator unless explicitly stated in a separate agreement.

Patent expiry and loss-of-exclusivity dates may be estimates when derived from grant date or bulk patent metadata. Confirm material dates against the USPTO, FDA Orange Book, or counsel before contractual or regulatory decisions.

Verify critical facts using the primary sources below. See our data sources policy (methodology) and privacy policy.

Last data refresh: May 23, 2026